Viking Therapeutics (NASDAQ:VKTX) Announces Earnings Results

Viking Therapeutics (NASDAQ:VKTX) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.03, Fidelity Earnings reports.

Shares of Viking Therapeutics stock traded down $0.27 on Thursday, reaching $5.96. 2,025,358 shares of the stock were exchanged, compared to its average volume of 1,063,560. The firm’s 50 day moving average is $6.85 and its 200-day moving average is $7.13. Viking Therapeutics has a one year low of $5.85 and a one year high of $11.03. The firm has a market cap of $460.32 million, a PE ratio of -18.06 and a beta of 2.35.

VKTX has been the subject of a number of recent research reports. B. Riley initiated coverage on shares of Viking Therapeutics in a report on Thursday, November 21st. They issued a “buy” rating and a $16.00 price objective for the company. BidaskClub downgraded shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, January 16th. Maxim Group reissued a “buy” rating and issued a $14.00 price objective on shares of Viking Therapeutics in a report on Wednesday, November 6th. Svb Leerink reissued an “outperform” rating on shares of Viking Therapeutics in a report on Thursday, January 2nd. Finally, ValuEngine downgraded shares of Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $17.32.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Featured Story: How is the discount rate different from the Federal Funds rate?

Earnings History for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.